Faze Three Management Change
Faze Three Limited has appointed Mr. Mohit Dinesh Solanki as an Independent Director for a five-year term effective August 17, 2026. The appointment was approved at the AGM.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Faze Three Limited has appointed Mr. Mohit Dinesh Solanki as an Independent Director for a five-year term effective August 17, 2026. The appointment was approved at the AGM.
Faze Three Limited concluded its 41st Annual General Meeting on September 4, 2026. Shareholders transacted ordinary and special business resolutions.
Faze Three Limited has submitted the First Supplemental Trust Deed of its Employee Trust to the stock exchanges. This amendment records changes in the appointed trustees.
Faze Three Limited submitted its 41st Annual Report for FY 2025-26 and the Notice convening the 41st Annual General Meeting scheduled for September 04, 2026.
Faze Three Limited issued a notice for its 41st Annual General Meeting on September 4, 2026. The agenda includes director appointments and borrowing limit approvals.
Faze Three Ltd. has dispatched letters to shareholders with unregistered email addresses, providing a weblink to access the Integrated Annual Report for FY 2025-26.
Faze Three reported highest-ever Q1 revenue of INR 235 Cr (+8.9% YoY) but faced margin compression due to West Asia crisis-led input cost spikes.
Faze Three Limited has appointed Mr. Mohit Solanki as an Additional Director. Simultaneously, Mr. Vinit Rathod ceased to be an Independent Director upon tenure completion.
Faze Three Ltd reported revenue from operations of ₹229.4 Cr (+8.2% YoY) and net profit of ₹9.6 Cr (-25.0% YoY) for Q1 FY27.
Faze Three Limited allotted 2,78,840 equity shares to its Employee Stock Option (ESOP) Trust. The company also announced changes to the Trust's trustees.
Faze Three Limited has scheduled a board meeting for August 11, 2026. The meeting will consider and approve unaudited standalone and consolidated financial results for Q1 FY2026-27.
Faze Three Ltd submitted its quarterly shareholding pattern as of June 30, 2026, detailing promoter holdings and information regarding its ESOP scheme grants.
CARE Ratings reaffirmed Faze Three Ltd's bank facilities totaling ₹280 crore. The rating remains CARE A (Long‑term) and CARE A1 (Short‑term) with a stable outlook.
Faze Three Ltd received approval under the PLI Scheme for MMF Fabrics and Technical Textiles. Incentives will be payable on incremental sales.
Faze Three Limited granted 3,31,154 employee stock options. The grant includes two price tiers with vesting periods ranging from one to five years.
Faze Three Limited granted 3,31,154 employee stock options under its 2024 ESOP scheme. Options have tiered pricing and varying vesting periods.
Mr. Manan Shah resigned as Independent Director of Faze Three Ltd effective June 10, 2026. The resignation is due to personal reasons with no material concerns stated.
Faze Three delivered record Q4FY26 revenue of ₹280 Cr and EBIDTA of ₹37 Cr. Strategy focuses on high-capacity utilization and structural tailwinds like 'China+1'.
Faze Three Ltd reported revenue from operations of ₹277.2 Cr (+31.6% YoY) and net profit of ₹19.6 Cr (+12.6% YoY) for Q4 FY26.
Faze Three Limited approved its audited standalone and consolidated financial results for fiscal year 2026. The results received an unmodified opinion from statutory auditors MSKA & Associates.
Faze Three Limited scheduled a board meeting on May 22, 2026. Directors will consider and approve audited financial results for the quarter and year ended March 2026.
Faze Three Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the period ending March 31, 2026. The certificate, issued by MUFG Intime India, confirms that security certificates received for dematerialisation were processed and substituted in the register of members within prescribed timelines.